title: Hyperdiploid karyotypes in acute myeloid leukemia define a novel entity: a study of 38 patients from the Groupe Francophone de Cytogenetique Hematologique (GFCH).
abstract: A series of 38 patients with acute myeloblastic leukemia (AML) with 49 or more chromosomes and without structural abnormalities was selected within the Groupe Francophone de Cytogénétique Hématologique (GFCH) to better define their characteristics. The median age of the patients was 65 years, and all FAB subtypes were represented. Although all chromosomes were gained, some seems to prevail: chromosome 8 (68%), 21 (47%), 19 (37%), and 13 and 14 (34% each). Since MLL rearrangement leads patients in a group with an unfavorable prognosis, search for cryptic rearrangements of MLL was performed in 34 patients and showed abnormalities in 5 (15%). When we applied the most frequent definition of complex karyotypes (three or more abnormalities), all patients with high hyperdiploid AML fall in the unfavorable category. Among the 18 patients without MLL rearrangement receiving an induction therapy, 16 (89%) reached CR and 6 (33%) were still alive after a 31-month median follow-up (14-61 months). Although this study was retrospective, these results suggest that high hyperdiploid AML without chromosome rearrangement seems to be a subgroup of uncommon AML (less than 1%), and may be better classified in the intermediate prognostic group.
authors.affiliation: Department of Cytogenetic, Hôpital Robert Debré, Reims, France.
authors.forename: I
authors.initials: I
authors.lastname: Luquet
authors.forename: J L
authors.initials: JL
authors.lastname: Laï
authors.forename: C
authors.initials: C
authors.lastname: Barin
authors.forename: L
authors.initials: L
authors.lastname: Baranger
authors.forename: C
authors.initials: C
authors.lastname: Bilhou-Nabera
authors.forename: E
authors.initials: E
authors.lastname: Lippert
authors.forename: C
authors.initials: C
authors.lastname: Gervais
authors.forename: P
authors.initials: P
authors.lastname: Talmant
authors.forename: P
authors.initials: P
authors.lastname: Cornillet-Lefebvre
authors.forename: C
authors.initials: C
authors.lastname: Perot
authors.forename: N
authors.initials: N
authors.lastname: Nadal
authors.forename: M J
authors.initials: MJ
authors.lastname: Mozziconacci
authors.forename: M
authors.initials: M
authors.lastname: Lafage-Pochitaloff
authors.forename: V
authors.initials: V
authors.lastname: Eclache
authors.forename: F
authors.initials: F
authors.lastname: Mugneret
authors.forename: C
authors.initials: C
authors.lastname: Lefebvre
authors.forename: C
authors.initials: C
authors.lastname: Herens
authors.forename: F
authors.initials: F
authors.lastname: Speleman
authors.forename: H
authors.initials: H
authors.lastname: Poirel
authors.forename: I
authors.initials: I
authors.lastname: Tigaud
authors.forename: C
authors.initials: C
authors.lastname: Cabrol
authors.forename: P
authors.initials: P
authors.lastname: Rousselot
authors.forename: S
authors.initials: S
authors.lastname: Daliphard
authors.forename: M
authors.initials: M
authors.lastname: Imbert
authors.forename: R
authors.initials: R
authors.lastname: Garand
authors.forename: F
authors.initials: F
authors.lastname: Geneviève
authors.forename: R
authors.initials: R
authors.lastname: Berger
authors.forename: C
authors.initials: C
authors.lastname: Terre
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics*; D005260:Female; D015321:Gene Rearrangement; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics; D011003:Ploidies; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies
chemical_list: C497422:KMT2A protein, human; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase